Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. (Q42641839)
Jump to navigation
Jump to search
scientific article published on 20 November 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. |
scientific article published on 20 November 2009 |
Statements
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics (English)
Laurent Boccon-Gibod
Kurt Miller
Fritz Schröder
Neal Shore
E David Crawford
Judd Moul
Jens-Kristian Jensen
Tine Kold Olesen
Bo-Eric Persson
20 November 2009